ghk cu peptide injection site GHK-CU best injection sites for ghk-cu

This origin should be understood as a biochemical research background, not as evidence of clinical use, consumer suitability, or therapeutic validation

Oral administration (capsule or lozenge) is more convenient and may be appropriate when the primary goal is GI support, since BPC-157 is remarkably stable in gastric juice

The FDA plans to meet to discuss another five peptides by the end of February 2027

This proposed connection to GILZ-mediated signalling could help explain DSIPs anti-inflammatory effects and its capacity to modulate immune function, though this remains a hypothesis under investigation

Future high-quality clinical and experimental studies are needed